December 8th, 2021
PEP-Therapy is recruiting a Business Analyst to support the development of the company after our series-A and the entry into the clinic of our lead product.
Check out the job offer.
November 4th, 2021
We are looking for a Medical Director / Chief Medical Officer !
Our lead compound, PEP-010, is in Phase Ia/b clinicaltrials, and we are seeking a MD with hands-on experience in the development of early stage oncology drugs in industry, to lead the clinical development.
If you are interested, please contact us.
October 27th, 2021
PEP-Therapy is recruiting a trainee to support the R&D activity. Check out the internship opportunity.
October 5th, 2021
PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors.
July 19th, 2021
PEP-Therapy extends Series-A financing, raising a total of €5.4 million to progress the clinical development of its lead candidate, PEP-010.
April 22nd, 2021
PEP-Therapy raises €2.75 million in Series A financing to advance its lead drug candidate in oncology, PEP-010, into clinical trials.
October 2nd, 2019
PEP-Therapy is proud to be part of the laureates of ReAliZe, the open innovation program of AstraZeneca in oncology.
April 17th, 2018
PEP-Therapy, Institut Curie and Gustave Roussy join together to conduct the Clever-Peptide project.
It aims at the development of an innovative anti-cancer peptide, firstly for the treatment of triple-negative breast cancer, and its companion biomarker, predictive of treatment efficacy. Approved by the Medicen Paris Region cluster, this collaborative project obtains 2,9 M€ funding.
May 12th, 2017
PEP-Therapy took part in the 3rd edition of the MEET2WIN business convention organized by MATWIN in Bordeaux on May 11th and 12th, dedicated to open innovation, collaborative research and technology transfer in oncology.
PEP-Therapy was awarded a prize as one of the 2 best pitch presentations.
December 13th, 2016
PEP-Therapy was proud to take part in “The Investment Plan for Europe: delivering results” seminar at the European Commission on November 29th.
One major pillar of the Plan is the European Fund for Strategic Investments (EFSI).
PEP-Therapy is one of the approved EFSI project. The company received €1 million support from Quadrivium 1, a French investment fund that received a €20 million injection from the European Investment Fund (EIF).
Both partners are featured in the Investment plan for Europe summary document.
+ Read more
October 28th, 2016
PEP-Therapy took part in the 3rd edition of the MedStartUp days at the Alexandria Center For Life Science in New York.
MedStartUp, organized by the Galien Foundation and Business France, bring together highly innovative French companies in the healthcare industry and American leaders in the pharma, medtech and digital health industries, to encourage and reward new transatlantic partnerships.
July 9th, 2016
PEP-Therapy and partners have been awarded a European H2020 grant to fight eye cancer for the next 5 years.
Under the coordination of Institut Curie, UM Cure 2020 is a new European consortium involving 12 partners to foster research on metastatic uveal melanoma (UM), a rare disease.
UM Cure 2020 has received €6 million of funding to develop new therapeutic approaches to treat metastatic UM.
November 20th, 2015
The finalists presented their venture at the 2015 Science|Business annual summit in Barcelona, where leaders from research, industry and policy have debated how best unleash Europe’s technological potential.
+ Watch the video
November 3rd, 2015
PEP-Therapy is very pleased to be profiled in this week BioCentury issue.
+ read the article
April 27th, 2015
The company is undertaking development of its first drug candidate and its companion diagnostic in oncology.
BiotechFinances is talking about it here.